Niraparib + Anlotinib
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum-resistant Recurrent Clear Cell Ovarian Cancer
Conditions
Platinum-resistant Recurrent Clear Cell Ovarian Cancer
Trial Timeline
Dec 15, 2021 → Jan 1, 2023
NCT ID
NCT05130515About Niraparib + Anlotinib
Niraparib + Anlotinib is a phase 2 stage product being developed by Sun Pharmaceutical for Platinum-resistant Recurrent Clear Cell Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05130515. Target conditions include Platinum-resistant Recurrent Clear Cell Ovarian Cancer.
What happened to similar drugs?
0 of 3 similar drugs in Platinum-resistant Recurrent Clear Cell Ovarian Cancer were approved
Approved (0) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05130515 | Phase 2 | Completed |
Competing Products
16 competing products in Platinum-resistant Recurrent Clear Cell Ovarian Cancer